Skip to main content

Graeme McRae, CEO of Bioniche Life Sciences Inc., poses for a photo in the company's animal vaccination facility in Belleville, Ont., on March 26, 2012. A battle for control of Bioniche has heated up, with a dissident group opposed to attempts to sell the company’s animal health business.

Michelle Siu/The Globe and Mail

The fight for control of Ontario biotechnology firm Bioniche Life Sciences Inc. has heated up, with a dissident group trying to call a special meeting of shareholders, which the company rejects as an "inappropriate and invalid" move.

The leader of the dissident faction, former Biovail Inc. chief executive officer Bill Wells, has called the special meeting for Aug. 27. Mr. Wells wants to present an alternative board of directors and oust the current Bioniche CEO Graeme McRae.

Mr. Wells said his group has the right to call the meeting because it owns more than 5 per cent of Bioniche shares, and the current board and management has refused requests for a shareholders' meeting.

Story continues below advertisement

Bioniche, for its part, said the proposal is improper because the company has already set a meeting for Nov. 5. In a statement Friday, it also noted that Mr. Wells' group has already initiated court proceedings to try to force a meeting. Trying to set up an August meeting is "in total disregard for the court process," the company said.

Mr. Wells objects to the efforts of current Bioniche management to try to sell the company's animal health business, which generates most of its revenue and cash flow. "If the sale is completed, it would permanently impair Bioniche and destroy shareholder value," his group said in a statement.

The remaining human health business, which is mainly focused on a cancer drug, "is still years away from producing any meaningful revenue," Mr. Wells said in a letter to shareholders.

Bioniche has promised that if they find a buyer for the animal health business, the sale will be put to a shareholder vote.

The fight between the two sides has become increasingly bitter. Mr. Wells' group has declared that the current board "continues to mismanage the company." Bioniche calls Mr. Wells' moves "increasingly aggressive public attacks" which "have the potential to jeopardize the very important initiatives underway to maximize the company's asset value."

Mr. Wells ran Biovail from 2008 to 2010, a period when that company refocused its product line and its shares more than doubled in value. He left Biovail shortly after it merged with Valeant Pharmaceuticals International Inc. late in 2010.

Bioniche shares are less than a quarter the value they were at near the beginning of 2011.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.